My statement assumes that we receive some sort of accelerated approval for mild-to-moderate, and/or severe populations, following a interim data review (yes a big assumption)


I'm not sure your license idea holds much water. In addition to blafarm's point:

You can't just "license" the rights to produce leronlimab and it is magically available. Aside from huge IP concerns, this isn't like making BIC pens. Without going into it, A LOT goes into getting a plant ready including money, time, and resources. IMO having been on a team that does this very thing, I would anything less than 6 months is impossible. 6 months would be with cutting more corners than any professional would be comfortable with in my opinion.

Given the timing alone, that doesn't seem like a good idea or any single national

Also, my post is not about people from Asia being any different from people anywhere else in the world, its matter of politics that exist in the US and about the reality of the current situation. Not saying it's fair or just.